Buy Article Permissions and Reprints Abstract

Objective Preterm infants often develop relative adrenal insufficiency (RAI) not only within the early neonatal period but also beyond this period. RAI is commonly accompanied by hyponatremia, but the pathogenesis of hyponatremia with RAI has not been clarified. This study aimed to investigate the pathophysiology of hyponatremia in infants with RAI.

Study Design This is a single-centered retrospective cohort study. Preterm infants born at <30 weeks of gestation or birth weight <1,000 g were enrolled. They were divided into the RAI group and the non-RAI group. The data of serum and urine examination, the amount of sodium intake, and fractional excretion of sodium (FENa) were compared between the two groups. In the RAI group, data before and after the administration of hydrocortisone were also compared.

Results Sixteen infants in the RAI group and 35 infants in the non-RAI group were included in the analysis. In the RAI group, hyponatremia was common and preceded other clinical symptoms, such as oliguria and decreased blood pressure, therefore, hyponatremia with RAI was not likely to be caused by dilution due to oliguria. There was no difference in the FENa between the two groups (adjusted for postconceptional age at examination), therefore, it is not likely that hyponatremia with RAI was mainly caused by excessive renal sodium loss. Since sodium intake was rather higher in the RAI group than in the non-RAI group, it is unlikely that insufficient sodium supplementation was the cause of RAI. Hyponatremia with RAI was considered to be likely caused by vascular hyperpermeability.

Conclusion Hyponatremia is a common symptom among preterm infants with RAI and its pathogenesis can be vascular hyperpermeability.

Key Points

The pathogenesis of hyponatremia with RAI can be vascular hyperpermeability.

Hyponatremia is common among preterm infants with RAI.

Hyponatremia with RAI preceded other clinical symptoms.

Keywords hyponatremia - relative adrenal insufficiency - preterm - infant - sodium - vascular hyperpermeability - hydrocortisone Ethical Approval and Consent to Participate

Patient consent was not required because this study was a retrospective cohort study. Information on this study was made available on a website and the participants were guaranteed the opportunity to opt out. This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Kyoto University Graduate School and the Faculty of Medicine Ethics Committee (approval no.: R3348).

Data Availability

All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

Authors' Contributions

M.A., S.T., S.H., R.A., H.T., K.I., and M.K. made significant contributions to conception and design, data acquisition, or data analysis and interpretation.

M.A., S.T., K.M., Y.T., J.T., and M.K. drafted or critically revised the article for important intellectual content.

All authors gave final approval to the published version.

Publication History

Received: 05 May 2024

Accepted: 10 September 2024

Accepted Manuscript online:
11 September 2024

Article published online:
30 September 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA